Get started
Author

Chong Ming Yeo

Observed names: C.M. Yeo, Chong Meng Yeo
Observed institutions: Inova Health System, Johns Hopkins University, Inova Fairfax Hospital, Tan Tock Seng Hospital, National University Cancer Institute, Singapore, National Healthcare Group
ORCID: 0000-0003-0353-1686
Observed ORCID: 0000-0003-0353-1686
OpenAlex ID: A5022237889
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial
2021 · R.A. Soo, J.-Y. Han, et al. · Annals of Oncology · 112
Abiraterone or Enzalutamide in Advanced Castration-Resistant Prostate Cancer: An Indirect Comparison
2017 · Akhil Chopra, Mina Georgieva, et al. · The Prostate · 34
Prevalence and risk factors of methotrexate hepatoxicity in Asian patients with psoriasis
2013 · Chong Meng Yeo, Vui Heng Chong, et al. · World Journal of Hepatology · 33
PDF
VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial
2021 · R. Soo, J-Y. Han, et al. · Annals of Oncology · 7
PDF
ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
2024 · Ross A. Soo, Urania Dafni, et al. · Clinical Cancer Research · 4
Financial toxicity among adult cancer survivors in Singapore: does it exist?
2023 · Ivy Weishan Ng, Kah Hung Yuen, et al. · Singapore Medical Journal · 2
Combining plasma and tissue next-generation sequencing provides optimal treatment selection for metastatic NSCLC: A comparative study.
2023 · Jens Samol, Lavina D. Bharwani, et al. · Journal of Clinical Oncology · 1
T4 cervical esophageal cancer cured with modern chemoradiotherapy: A case report
2020 · Chia Ching Lee, Chong Ming Yeo, et al. · World Journal of Clinical Cases · 1
Supplementary Figure S3 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
2024 · Ross A. Soo, Urania Dafni, et al.
PDF
Supplementary Figure S7 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
2024 · Ross A. Soo, Urania Dafni, et al.
Supplementary Figure S5 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
2024 · Ross A. Soo, Urania Dafni, et al.
PDF
Supplementary Figure S8 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
2024 · Ross A. Soo, Urania Dafni, et al.
Supplementary Tables S1-S14 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
2024 · Ross A. Soo, Urania Dafni, et al.
Data from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
2024 · Ross A. Soo, Urania Dafni, et al.
Supplementary Figure S4 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
2024 · Ross A. Soo, Urania Dafni, et al.
PDF
Supplementary Figure S11 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
2024 · Ross A. Soo, Urania Dafni, et al.
Supplementary Figure S2 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
2024 · Ross A. Soo, Urania Dafni, et al.
Supplementary Figure S1 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
2024 · Ross A. Soo, Urania Dafni, et al.
PDF
Supplementary Appendix S1 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
2024 · Ross A. Soo, Urania Dafni, et al.
Supplementary Figure S9 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
2024 · Ross A. Soo, Urania Dafni, et al.
Supplementary Figure S10 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
2024 · Ross A. Soo, Urania Dafni, et al.
Supplementary Figure S6 from ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial
2024 · Ross A. Soo, Urania Dafni, et al.
PDF
Does Financial Toxicity Exist Amongst Adult Cancer Survivors Treated With Definitive Radiotherapy? A Pilot Study from Singapore
2020 · I.W. Ng, O. Yuen, et al. · International Journal of Radiation Oncology*Biology*Physics
PDF
1033 Prevalence and Risk Factors of Liver Fibrosis Associated With Methotrexate in an Asian Psoriatic Population
2009 · C.M. Yeo, W.L. Yang, et al. · Journal of Hepatology
Works count: 25
Citation count: 306
H-index: 5
I10-index: 4
Year
Topic
Type